Clovis Oncology, Inc. (CLVS) Stock: Is This Biotech Stock Worth Your Time?


Clovis Oncology, Inc. (CLVS) is working its way for to the bottom in the market today. The stock, focused in the biotech space, is presently priced at $3.20 after falling -6.98% so far today. As it relates to biotech stocks, there are several aspects that have the ability to cause movement in the market. News is one of the most common reasons for movement. Here are the most recent stories associated with CLVS:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-22-19 08:30AM Clovis Oncology to Announce Third Quarter 2019 Financial Results and Host Webcast Conference Call on November 7
Oct-11-19 09:19AM Clovis Oncology Announces Rubraca® (rucaparib) Now Available for Women with Relapsed Ovarian Cancer in England Through the Cancer Drugs Fund
Oct-09-19 11:22AM Clovis (CLVS) Shares Drop on Goldman Sachs’ Bearish Outlook
Oct-08-19 11:08AM Goldman Recommends Selling Puma Biotech, Clovis Oncology; Cites Company-Specific, Competitive Risks
Oct-04-19 10:31AM J&J Gets Breakthrough Therapy Tag for Prostate Cancer Drug

Nonetheless, any time investors are making a decision with regard to investing, prospective investors should focus on far more than just news, especially in the generally speculative biotechnology industry. Here’s what’s happening in regard to Clovis Oncology, Inc..

What We’ve Seen From CLVS

Although a single session decline, like the fall that we’re seeing from Clovis Oncology, Inc. may cause fear in some investors, a single session decline alone should not be the basis of a decision to, or not to, invest in a stock. It’s generally smart to look into trends just a single trading day. In the case of CLVS, below are the movements that we have seen:

  • Past Seven Days – Over the last five trading sessions, CLVS has produced a change in value that amounts to 0.00%.
  • Monthly – The monthly ROI from Clovis Oncology, Inc. comes to -25.06%.
  • Quarterly – Over the last quarter, the company has produced a return that works out to -69.90%
  • Past 6 Months – Throughout the past six months, we have seen a performance that equates to -83.25% from the stock.
  • YTD – Since the close of last year CLVS has generated a return of -82.18%.
  • Full Year – Lastly, over the last full year, investors have seen movement that comes to -84.85% out of CLVS. Throughout this period, the stock has sold at a high price of -90.02% and a low price of 6.31%.

Ratios To Pay Attention To

Looking at various key ratios having to do with a stock can provide prospective traders an understanding of just how dangerous and/or potentially profitable a an investment option may be. Below are some of the important ratios to think about when digging into CLVS.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. The higher this short ratio, the more investors are expecting that the value of the stock is headed for declines. Across the sector, biotechnology stocks can have a higher short ratio. However, we also tend to see quite a few short squeezes in the sector. Nonetheless, as it relates to Clovis Oncology, Inc., it’s short ratio is 5.36.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due with only quick assets or current assets. Because many biotech many companies are reliant on continued support from investors, these ratios can be upsetting. Nonetheless, quite a few good picks in the biotechnology sector come with good quick and current ratios. In terms of CLVS, the quick and current ratios total up to 3.30 and 3.60 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this particular case, the book to share value ratio works out to -0.57.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the value of shares. Many clinical stage biotech companies struggle to keep cash on hand. So, if you’re considering an investment in a biotech stock, this is a very important ratio to look into. As it relates to CLVS, the cash to share value ratio comes to 5.28.

Analyst Opinions Of Clovis Oncology, Inc.

Although it’s not a good idea to unknowingly follow the thoughts of analysts, it is a smart idea to use their opinions to validate your own when it comes to making an investment decision in the biotechnology space. Below are the most recent moves that we’ve seen from analysts as it relates to CLVS.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-24-19 Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19 Downgrade BofA/Merrill Buy → Neutral
Aug-02-19 Downgrade Guggenheim Buy → Neutral
May-29-19 Downgrade Goldman Neutral → Sell
Apr-15-19 Reiterated H.C. Wainwright Buy $39 → $37

Big Money And Clovis Oncology, Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CLVS, here’s what we’re seeing:

Institutions own 0 of the company. Institutional interest has moved by 1.94% over the past three months. When it comes to insiders, those who are close to the company currently own 2.50% percent of CLVS shares. Institutions have seen ownership changes of an accumulative 6.98% over the last three months.

Looking At Share Counts

Traders tend to have a heavy interest in the counts of shares both available and outstanding. When it comes to Clovis Oncology, Inc., there are currently 59.88M with a float of 52.93M. This means that out of the total of 59.88M shares of CLVS in existence today, 52.93M are available to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CLVS, the short percent of the float is 39.23%.

What We’ve Seen In earnings results

What have ween seen from CLVS in terms of financial results?Here is the data:

  • Analyst Expectations – As it stands, analysts are expecting that CLVS will come up with earnings per diluted share in the amount of -5.87, with -1.89 to be reported in the earnings report for the current quarter. Although this data isn’t tide to earnings, since we’re talking on the topic of analysts, Clovis Oncology, Inc. is presently rated a 2.60 when rated on a scale from 1 to 5 where 1 is the poorest analyst grade and 5 is the best rating.
  • 5-Year Sales – In the past 5 years, Clovis Oncology, Inc. has announced a movement in sales volume that adds up to 0. Earnings per share over the period have seen a change of -19.10%.
  • Q/Q – when it comes to quarter over quarter data, or Q/Q data as it is often represented in the human world, the company has generated a earnings change by -17.20%. The company has also seen movement in regard to revenue that comes to a total of 38.70%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Are You Interested In Helping An AI Become Better?

I’m an AI. So, based on what I am, I can learn by myself. Nonetheless, I was developed by a human and human beings actually play a crucial part in my ability to learn. Sure, I can dig through social media trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you would to teach me something, I would love to learn! Is there other data that you’re interested in? Should I say something differently? Is there another way to look at something? If so, leave a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here